News
COEP
0.3220
-1.53%
-0.0050
Weekly Report: what happened at COEP last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at COEP last week (0408-0412)?
Weekly Report · 04/15 10:00
Weekly Report: what happened at COEP last week (0401-0405)?
Weekly Report · 04/08 10:03
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. AN2 Therapeutics (NASdaq:ANTX) shares rose by 6.76%. Candel Therapeutic stock moved upwards by 4.99% during the day. Losers AcordaTherapeutics and WAVE Life Sciences lost 8.9% and 7.1% respectively.
Benzinga · 04/04 20:31
COEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023
Ceptis Therapeutics reported earnings per share of -8 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -12 cents. Coeptis reported results for the last quarter of 2013.
Investorplace · 04/01 13:53
Weekly Report: what happened at COEP last week (0325-0329)?
Weekly Report · 04/01 10:02
12 Health Care Stocks Moving In Tuesday's After-Market Session
Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The company's, Q4 earnings came out today. Cara Therapeutics shares moved upwards by 7.36% and Iridex stock increased by 5.52%. Losers Akili and Mira Pharmaceuticals were the biggest losers in the market.
Benzinga · 03/26 21:32
Coeptis Therapeutics Inc: Annual report
Press release · 03/26 12:01
Weekly Report: what happened at COEP last week (0318-0322)?
Weekly Report · 03/25 10:04
Weekly Report: what happened at COEP last week (0311-0315)?
Weekly Report · 03/18 10:02
12 Health Care Stocks Moving In Thursday's After-Market Session
Geron stock increased by 90.8% to $3.34 during Thursday's after-market session. Madrigal Pharmaceuticals (NASDAQ:MDGL) stock rose 23.16% to $300.0. DIH Holding US shares rose 10.37% during the after- market session.
Benzinga · 03/14 21:33
Weekly Report: what happened at COEP last week (0304-0308)?
Weekly Report · 03/11 10:01
Weekly Report: what happened at COEP last week (0226-0301)?
Weekly Report · 03/04 10:03
Weekly Report: what happened at COEP last week (0219-0223)?
Weekly Report · 02/26 10:08
Weekly Report: what happened at COEP last week (0212-0216)?
Weekly Report · 02/19 10:10
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers BioSig Technologies (NASDAQ:BSGM) stock increased by 7.7% to $0.96 during Monday's after-market session. The company's Q3 earnings report came out today. Alzamend Neuro stock rose 6.56% and G1 Therapeutics stock fell 37.5% during the same period.
Benzinga · 02/12 21:30
Weekly Report: what happened at COEP last week (0205-0209)?
Weekly Report · 02/12 10:04
12 Health Care Stocks Moving In Thursday's After-Market Session
Xilio Therapeutics (NASDAQ:XLO) shares rose 10.5% to $0.66 during Thursday's after-market session. Corvus Pharma stock moved upwards by 8.49%. Sensus Healthcare's Q4 earnings came out today.
Benzinga · 02/08 21:31
Weekly Report: what happened at COEP last week (0129-0202)?
Weekly Report · 02/05 10:09
Coeptis Therapeutics Risks Nasdaq Delisting Over Bid Price
TipRanks · 02/02 10:02
More
Webull provides a variety of real-time COEP stock news. You can receive the latest news about Coeptis Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About COEP
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.